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ORIGINAL ARTICLES
Treatment of Steroid-Induced Elevated Intraocular
Pressure with Anecortave Acetate:
A Randomized Clinical Trial
Ingeborg Stalmans,1 David G. Callanan,2,3 Monte S. Dirks,4 Marlene R. Moster,5,6
Alan L. Robin,7,8 Joachim Van Calster,1 Sally A. Scheib,9 Jaime E. Dickerson, Jr.,10,11
Theresa A. Landry,9 and Michael V.W. Bergamini12,13
Abstract
Purpose: The present study is the first randomized clinical trial designed to evaluate the intraocular pressure
(IOP)-lowering effect of anecortave acetate (AA) administered at 3 doses (3, 15, or 30mg) as an anterior jux-
tascleral depot (AJD) in patients experiencing elevated IOP due to corticosteroid therapy.
Methods: This was a double-masked, randomized, placebo-controlled, multicenter, parallel group trial. Eligible
patients had an IOP of at least 24mmHg and an IOP increase of at least 10mmHg relative to their IOP before
treatment with steroids. A target IOP was established for each patient at baseline. Patients were randomized to 1
of the 4 treatment groups: vehicle, 3mg AA, 15mg AA, or 30mg AA. All patients then received a 0.5mL AJD of
the assigned treatment. Patients returned for scheduled examination visits at weeks 1, 2, 4, 6, months 3, 4, 5, and
6. IOP was measured at each visit as well as best corrected visual acuity (logMAR), ocular motility, eyelid
responsiveness, slit lamp examination, and assessment of any adverse events. In addition, at baseline and at exit,
a dilated fundus examination was carried out and the lens was examined using LOCS II criteria.
Results: Seventy patients were randomized to treatment. At week 4, eyes in the vehicle group showed a
3.4mmHg (9.1%) decrease from baseline. Reductions for the 3mg AA (3.1mmHg, 10.7%) and the 30mg AA
groups (5.4mmHg, 16.6%) were not significantly different than for vehicle control. However, IOP for the 15mg
AA group at week 4 was reduced 11.5mmHg (31.3%) from baseline, which was statistically significant
(P = 0.0487). The mean time to treatment failure was 32.2, 38.9, 56.3, and 32.6 days for the vehicle, 3mg AA,
15mg AA, and 30mg AA groups, respectively. Adverse events were assessed at each post-treatment visit. There
were no serious adverse events that were determined to be related to the test article or its administration.
Conclusions: AA can be of benefit to some patients requiring treatment with corticosteroids, but suffering from
the side effect of elevated IOP.
Introduction
Corticosteroids are important in the management ofmany serious systemic diseases as well as sight-threat-
ening ocular conditions, including uveitis, vein occlusions,
age-related macular degeneration, and macular edema.1,2
The utility of these drugs in the treatment of ocular disease is
tempered by well-known side effects, including cataract3 and
elevated intraocular pressure (IOP).1,2 Because of these side
effects, in particular elevated IOP, alternative treatment
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modalities have been sought. Antimetabolite drugs,4
NSAIDs,5,6 vascular endothelial growth factor antagonists,7,8
surgical,9 and gene therapy10 methods to prevent or ame-
liorate the steroid-induced elevated IOP have been explored.
Anecortave acetate (AA) is a cortisene, a synthetic deriv-
ative of cortisol. Removal of the 11 b-OH group from corti-
sol’s B ring and introduction of a C9–11 double bond renders
AA devoid of glucocorticoid receptor agonist activity.11
AA has 2 inherent pharmacological activities; it has anti-
angiogenic properties through inhibition of the angio-
genic proteolytic cascade,11–13 and it has IOP-lowering
activity.14–16
AA has been shown to lower IOP in steroid-induced oc-
ular hypertensive patients in a case series of 8 eyes from 7
patients with medically uncontrolled IOP following in-
travitreal injections of triamcinolone acetonide.14 AA has also
been shown to lower IOP in steroid responsive sheep and to
prevent IOP elevation in the same model system.15 The
present study is the first randomized clinical trial designed to
evaluate the IOP-lowering effect of AA administered at 3
doses (3, 15, or 30mg) as an anterior juxtascleral depot (AJD)
in patients experiencing elevated IOP due to corticosteroid
therapy.
Methods
This was a double-masked, randomized, placebo-controlled,
multicenter, parallel group trial. The study was reviewed and
approved by the Sterling Institutional Review Board and by
local institutional review boards or ethics committees where
appropriate. All participating patients provided written in-
formed consent. The study was HIPAA compliant and was
conducted under the tenets of the Declaration of Helsinki.
The study protocol was registered on ClinicalTrials.gov
(NCT00315640).
This was a multicenter study conducted at 18 sites
throughout the United States, Europe, Mexico, and Brazil.
Eligible patients were of either sex, and any race, 18 years of
age or older, with an IOP of at least 24mmHg and who had
an IOP increase of at least 10mmHg relative to their IOP
before treatment with steroids.
Patients were excluded from the study for any of the fol-
lowing criteria: ocular trauma within the past 6 months in
the study eye; the presence of a scleral buckle; a cup-to-disc
ratio greater than 0.80 in either eye; any abnormality pre-
venting reliable applanation tonometry; anticoagulant ther-
apy other than antiplatelet therapy; evidence of scleral
thinning; pregnancy or the intent to become pregnant during
the study; breast feeding.
Patients under treatment with ocular hypotensive medi-
cations at the time of screening were allowed to enroll pro-
vided that they had at least 30 days stable dosing before
enrollment for these medications, and that the treatment
regimen was not changed during the study. Eligibility IOP
requirements were the same whether or not a patient was
receiving prestudy IOP-lowering therapy.
A target IOP was established by the investigators for each
patient who provided informed consent and met inclusion/
exclusion criteria at the screening/baseline visit. This target
IOP was at the investigators’ discretion and depended on the
individual characteristics of each patient, including baseline
IOP and health of the optic nerve. Following the setting of a
target IOP, patients were randomized to 1 of the 4 treatment
groups: vehicle, 3mg AA, 15mg AA, or 30mg AA. All pa-
tients then received a 0.5mL anterior sub-Tenon’s injection of
the assigned treatment. Before the injection, eyes were pre-
pared as follows: instillation of proparacaine HCl (Alcaine;
Alcon Laboratories, Fort Worth, TX) followed by placing 5%
povidone-iodine (Betadine; Alcon Laboratories) in the cul-
de-sac and closing the eye for at least 1min. A wire lid
speculum was inserted into the eye and the site of injection
was selected between 4 o’clock and 8 o’clock and at least
5mm posterior to the limbus in an area free of large con-
junctival or episcleral vessels. Additional proparacaine was
applied to the site of injection with a cotton swab or pledget
for a minimum of 30 s. Injections were carried out using a
30-g needle and Fechtner forceps (Katena Products, Inc.,
Denville, NJ) to grasp the conjunctiva. A drop of topical
antibiotic (e.g., moxifloxacin) was applied post-injection.
Each injection was recorded with a digital video camera. The
recordings were reviewed by the sponsor’s medical monitor
within 1 week to ensure that the AJD was given according to
standard procedure.
Patients returned for scheduled examination visits at
weeks 1, 2, 4, 6, months 3, 4, 5, and 6. IOP was measured at
each visit as well as best corrected visual acuity (logMAR),
ocular motility, eyelid responsiveness, slit lamp examination,
and assessment of any adverse events. In addition, at base-
line and at exit, a dilated fundus examination was carried out
and the lens was examined using the LOCS II criteria.
Beginning at week 4, investigators could rule a patient a
treatment failure and add appropriate rescue medication
according to the following criteria: if the patient’s IOP for the
study eye exceeded the established target IOP and remained
above the target IOP at a subsequent additional IOP check
(scheduled at the investigators discretion, generally within a
week). Patients ruled treatment failures remained in the
study for the full 6 months; however, the last IOP mea-
surement before the addition of rescue therapy was carried
forward for analysis for subsequent visits. Missing data, ei-
ther due to a missed visit or an early discontinuation for any
reason (e.g., withdrawn consent, adverse event, treatment
failure), was imputed using the method of last observation
carried forward. In the case of a treatment failure, this means
that the IOP carried forward for all subsequent visits was the
failed IOP. This is a conservative procedure as it does not
exaggerate the treatment effect of the drug at later study
visits by only considering successes.
The primary statistical objective of the study was to dem-
onstrate that AA (3, 15, and/or 30mg) was superior to the
placebo control with respect to IOP reduction. The primary
efficacy end point was mean change in IOP from baseline at
the week 4 visit. Hypothesis tests were performed using re-
peated measures analysis of variance. Multiplicity was ad-
justed using Hommel’s method. Secondary efficacy parameters
included the time to treatment failure and the percentage of
patients declared treatment failures. Kaplan-Meier survival
analysis was used to estimate times to treatment failure.
Planned enrollment was 60 patients. With 15 evaluable
patients per group, there is at least 95% power to demon-
strate a difference of ‡ 5mmHg between any 2 groups. This
sample size is based on a 2-sided t-test procedure with
a = 0.05 and an assumed standard deviation of 3.5mmHg.
With a standard deviation as high as 4.1mmHg, there would
still be approximately 90% power to achieve the planned
primary objective.
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Results
Seventy patients were randomized to treatment. All pa-
tients were evaluable for safety and for the intent-to-treat
(ITT) data sets. Eleven patients were excluded from the per
protocol (PP) data set (AA 3mg, n = 4; AA 15mg, n = 2; AA
30mg, n = 4; vehicle, n = 1) because of protocol violations.
These violations included less than 30 days stable dosing
with prestudy IOP-lowering medications (n= 7), history of
trabeculectomy in the study eye (n = 2), and nonqualifying
IOP (n = 2). Patient demographic data are tabulated in Table
1. Primary and secondary outcomes were similar for PP and
ITT data sets. The majority of patients were male, Caucasian,
under 65 years of age, and with brown irides. There were no
significant differences in demographics between the treat-
ment groups, although with respect to iris color, the vehicle
group had a majority of patients with blue irides. Thirty
percent (21 of 70) of the patients entering the study had prior
vitrectomy surgery in the study eye; 3 in the 3mg, 4 in the
15mg, 7 in the vehicle and 30mg groups. A sensitivity
analysis was carried out excluding those patients with prior
vitrectomy. There were no differences in conclusions based
on these results and those from the larger ITT data set.
Most patients (61 of 70) had been treated with triam-
cinolone acetonide before the study. These were primarily
intravitreal injections (57 of 61) and were in most cases the
patient’s first injection with triamcinolone (51 of 61). Pa-
tients who had multiple prestudy triamcinolone injections
were evenly distributed across the treatment groups (N = 2
or 3 per group). The average dose of triamcinolone acet-
onide was similar for the 3 AA treatment groups (11.7, 10.6,
and 11.4mg for the 3, 15, and 30mg groups respectively),
and was about twice that for the vehicle group (average
triamcinolone dose = 5.5mg). The interval between triam-
cinolone injection and administration of AA was also sim-
ilar across the 3 AA treatment groups (84, 88, and 79 days
for the 3, 15, and 30mg groups, respectively), but again,
was different for the vehicle group (average interval = 33
days). An additional sensitivity analysis was carried out
evaluating only those patients entering the study following
intravitreal triamcinolone acetonide (IVTA) treatment.
There were no differences in conclusions between the IVTA
only dataset, or for ITT.
Primary inference for this study was based on the com-
parisons of mean change from baseline in IOP at week 4 for
each of the AA active drug groups versus the vehicle group
(Fig. 1). At week 4, eyes in the vehicle group showed a
3.4mmHg (10%) decrease from baseline. Reductions for the
3mg AA (3.1mmHg, 10%) and the 30mg AA groups
(5.4mmHg, 16%) were not significantly different than for
vehicle control. However, IOP for the 15mg AA group at
week 4 was reduced 11.5mmHg (31%) from baseline, which
Table 1. Patient Demographics by Treatment Group
Treatment (N= 70)
Anecortave acetate 3mg Anecortave acetate 15mg Anecortave acetate 30mg Vehicle
Total N (18) % (25.7) N (17) % (24.3) N (18) % (25.7) N (17) % (24.3) Pa
Age (years)
< 65 13 72.2 14 82.4 11 61.1 12 70.6 0.5951
‡ 65 5 27.8 3 17.6 7 38.9 5 29.4
Mean – SD 61.2 12.6 53.0 11.6 59.9 10.0 54.2 17.5
Sex
Male 10 55.6 9 52.9 10 55.6 11 64.7 0.9063
Female 8 44.4 8 47.1 8 44.4 6 35.3
Race
White 13 72.2 13 76.5 17 94.4 17 100.0 0.1304
Black 4 22.2 2 11.8 1 5.6 0 0.0
Asian 0 0.0 1 5.9 0 0.0 0 0.0
Other 1 5.6 1 5.9 0 0.0 0 0.0
Iris color
Blue 6 33.3 5 29.4 6 33.3 9 52.9 0.2322
Brown 11 61.1 11 64.7 9 50.0 4 23.5
Grey 0 0.0 0 0.0 1 5.6 0 0.0
Hazel 1 5.6 1 5.9 2 11.1 4 23.5
aP value from w2 or Fisher exact test.
SD, standard deviation.
FIG. 1. Mean IOP change from baseline at week 4. Error
bars are 1 standard deviation. AA, anecortave acetate; IOP,
intraocular pressure. *Significantly different from baseline,
P = 0.0487.
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was statistically significant (P= 0.0487) and over 8mmHg
greater than seen in the control group. The mean IOP
changes from baseline and for percentage change in IOP, for
each visit by treatment group are given in Table 2. Baseline
IOP for the 4 treatments were similar (34.1, 31.1, 37.6,
32.9mmHg for vehicle, 3, 15, 30mg, respectively).
There was no significant difference in the frequency of
treatment failure at any visit; however, there were interesting
trends that are congruent with the IOP data. Survival curves
indicated that the frequency of treatment failure was highest
for the vehicle group at all time points. The 15mg AA group
had the lowest frequency of treatment failure at 5 of 7 time
points. At 6 months (exit visit), the 15mg group had 53% of
patients requiring additional IOP-lowering medication,
while the vehicle, 3mg AA, and 30mg AA groups were 77%,
67%, and 56%, respectively. These data are depicted as Ka-
plan-Meier plots in Fig. 2. For patients who were declared
treatment failures, the mean time to failure was 32, 39, 56,
and 33 days for the vehicle, 3mg AA, 15mg AA, and 30mg
AA groups, respectively.
Enrollment in this study was not evenly distributed across
the investigative sites. One site enrolled nearly one-third of
the patients (N = 23); 4 sites accounted for another 23 patients
with the remaining 24 patients distributed across 13 sites. To
evaluate the role that experience in administering the AJD
might play in the efficacy of treatment, the patients were
divided into 3 groups, high-enrolling site (N = 1), mid-
enrolling sites (N= 4), and low-enrolling sites (N= 13). Figure 3
plots the percentage of patients enrolled in each of these 3
groups who received active drug (the vehicle patients are
excluded) who were not treatment failures at week 4, month
3, and month 6 for each of these groups. The lowest rate of
success at all 3 time points was that for the low enrolling
group. The highest enrolling site had the greatest success rate
at 2 of 3 time points.
Adverse events were assessed at each post-treatment visit.
There were no serious adverse events that were determined
to be related to the test article or its administration. One
patient treated with AA 30mg discontinued the study early
due to a nonserious adverse event (macular edema), which
Table 2. Mean Intraocular Pressure Change from Baseline (mmHg) for All Visits (Intent-to-Treat)
Screening Week 1 Week 2 Week 4 Week 6 Month 3 Month 4.5 Exit visit
Vehicle
Mean (% chg) 34.1 - 4.1 (12) - 2.8 (8) - 3.4 (10) - 4.4 (13) - 4.6 (13) - 4.1 (12) - 4.8 (14)
SD 8.9 9.6 8.4 9.4 10.1 9.9 10.0 10.1
N 17 15 17 17 17 17 17 17
Median 31.0 - 5.0 - 4.0 - 2.0 - 4.0 - 4.0 - 2.0 - 4.0
Min 25 - 27 - 24 - 27 - 30 - 27 - 28 - 27
Max 60 8 7 9 10 10 10 10
AA 3mg
Mean (% chg) 31.1 - 3.7 (12) - 3.2 (10) - 3.1 (10) - 2.6 (8) - 3.0 (10) - 2.6 (8) - 2.7 (9)
SD 6.1 8.8 9.8 11.0 10.0 10.3 10.2 10.7
N 18 17 18 18 18 18 18 18
Median 29.0 - 3.0 - 3.0 - 5.5 - 3.0 - 3.0 - 3.0 - 2.5
Min 22 - 22 - 21 - 22 - 17 - 17 - 17 - 18
Max 44 19 19 19 19 19 19 19
AA 15mg
Mean (% chg) 37.6 - 4.1 (11) - 5.4 (14) - 11.5 (31) - 12.2 (32) - 11.4 (30) - 10.2 (27) - 9.8 (26)
SD 10.2 6.1 7.7 9.8 10.0 10.3 11.9 12.5
N 17 17 17 17 17 17 17 17
Median 34.0 - 5.0 - 7.0 - 12.0 - 11.0 - 12.0 - 11.0 - 11.0
Min 26 - 16 - 18 - 29 - 28 - 29 - 28 - 28
Max 65 9 9 7 7 7 13 13
AA 30mg
Mean (% chg) 32.9 - 4.2 (13) - 3.6 (11) - 5.4 (16) - 5.8 (18) - 5.8 (18) - 5.6 (17) - 5.9 (18)
SD 10.3 6.2 6.8 10.8 9.8 10.0 9.9 9.9
N 18 18 18 18 18 18 18 18
Median 30.0 - 2.5 - 3.5 - 5.5 - 6.0 - 6.0 - 5.0 - 6.0
Min 24 - 18 - 19 - 32 - 33 - 33 - 33 - 33
Max 61 4 7 18 16 16 16 16
AA, anecortave acetate; % chg, percent change in IOP from baseline; IOP, intraocular pressure.
FIG. 2. Kaplan-Meier plot showing time to treatment failure.
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was assessed as unrelated to the test article or the AJD
procedure. The most frequent adverse events associated with
either AA or the AJD procedure are listed in Table 3. Adverse
drug reactions included keratitis and worsening of cataract.
Procedural-related adverse events included conjunctival
hemorrhage, eye pain, and hyperemia. No dose-related trend
was observed for any adverse event, and the incidence of
adverse drug reactions and those related to the AJD proce-
dure were similar for the AA 3, 15, and 30mg groups.
Discussion
Corticosteroids are often necessary to provide effective
treatment for serious systemic and ocular inflammatory
conditions. Elevation of IOP is a known risk accompanying
the use of these drugs. In a study of 305 eyes from 272 pa-
tients given IVTA for various retinal pathologies, Jonas et al.
found that up to 40% of patients experienced an increase in
their IOP above 21mmHg.17 Similar results have also been
reported for a population of 147 Chinese patients18 and for a
group of 108 patients from the Southampton University Eye
Unit in the United Kingdom.19 Even more striking, pooled
data from 3 large multicenter trials of the sustained release
fluocinolone acetonide implant (Retisert; Bausch and Lomb,
Rochester, NY) found that 71% of implanted eyes had an IOP
increase of 10mmHg or more from baseline.20 Clearly, a
means to suppress or counter the IOP elevation, while not
interfering with the glucocorticoid receptor-mediated effects
of these drugs (i.e., anti-inflammatory, angiostatic) would
allow for a greater margin of safety with corticosteroid
therapy.
AA is one of a class of steroid-derived compounds known
to lower IOP, but devoid of conventional steroid hormone
activitiy.11 The precise molecular mechanism of action is not
well understood, however, it has been shown that it does not
bind the glucocorticoid receptor.21
AA has been reported to have IOP-lowering efficacy for
both steroid-induced elevated IOP,14 and for elevated IOP
associated with open-angle glaucoma.16 These were small
case series without a control group, and therefore, the true
magnitude of the treatment effect is difficult to interpret. The
IOP elevation produced by steroids eventually diminishes
and the pressure will return to baseline as the steroid effect
wears off. Thus, without a placebo control it is difficult to
distinguish between the expected ebbing of the steroid re-
sponse, and an actual IOP reduction produced by AA.
The present study employed a control group and 3 dif-
ferent doses of AA. The decrease in IOP with time seen in the
vehicle group (refer to Table 2) was almost certainly due to a
diminution of the steroid hypertensive effect with time. It
should be noted that the average dose of triamcinolone
acetonide for patients in the vehicle group was only about
half that received by the patients in the 3 AA groups (5.5mg
vs. approximately 11mg) and this could certainly have been
a factor in the large placebo effect seen at month 6. However,
the interval between triamcinolone and AA administration
was also shortest for the vehicle group (33 days vs. ap-
proximately 80 days) making it less likely that the steroid
effect had worn off relative to the 3 AA groups at month 1
(the primary end point). Prior history of vitrectomy in the
study eye could have resulted in more rapid clearance of
intravitreal triamcinolone, which could contribute to a de-
crease in IOP over time. Approximately one-third of the
FIG. 3. Percent treatment successes at week 4, and months
3 and 6 for low-, mid-, and high-enrolling sites. Treatment
success for patients randomized to active treatment defined
as IOP controlled without the use of adjunctive medications.
Low, sites enrolling 1–4 patients (13 sites, N = 24 patients);
mid, sites enrolling 5–7 patients (13 sites, N = 23 patients);
high, 1 site that enrolled 23 patients.
Table 3. Frequency and Incidence of Adverse Events Related to Anecortave Acetate
or the Anterior Juxtascleral Depot Procedure
AA 30mg AA 15mg AA 3mg Vehicle
N = 18 N= 17 N = 18 N = 17
N % N % N % N %
AEs related to AA
Cataract (worsening) 1 5.6 1 5.9 0 0.0 0 0.0
Keratitis 1 5.6 0 0.0 0 0.0 0 0.0
AEs related to the AJD procedure
Conjunctival hemorrhage 1 5.6 2 11.8 2 11.1 1 5.9
Eye pain 2 11.1 3 17.6 0 0.0 1 5.9
Hyperemia 0 0.0 0 0.0 1 5.6 1 5.9
Ocular discomfort 0 0.0 1 5.9 1 5.6 0 0.0
Blurred vision 1 5.6 0 0.0 0 0.0 0 0.0
Iritis 1 5.6 0 0.0 0 0.0 0 0.0
AE, adverse event; AJD, anterior juxtascleral depot.
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30mg AA group had a prior vitrectomy, while the 15mg
group had only half as many, making it unlikely that this
was an important factor in the overall efficacy. Of the 3 active
treatment groups, only the 15mg AA group was statistically
superior to vehicle. The 30mg AA group showed numeri-
cally greater reductions from baseline than did vehicle, and
perhaps with a larger sample size these differences would be
statistically significant.
At least half of all subjects receiving any dose of AA were
able to remain free of additional IOP-lowering medications at
1 month post-AA injection in contrast to only about one-third
in the vehicle group, a trend indicating an IOP-lowering
benefit for patients at all dose levels.
There were very few adverse events assessed as related to
AA. Two of the three that were reportedwere forworsening of
cataract. It is worth noting that a well-known side effect as-
sociated with corticosteroid treatment is the development of
cataract. It is therefore very likely that the cause of cataract
progression observed in these 2 patients was the original ste-
roid insult, and not the AA. Furthermore, AA’s lack of gluco-
corticoid activity casts additional doubt on its culpability.
A weakness of this study is the relatively small sample
size relative to the amount of variability in the data. Initial
power calculations were predicated on an assumed standard
deviation in the IOP measurements of 3.5mmHg as is com-
monly used for randomized clinical trials with glaucoma
patients.22 In fact, the standard deviation for the IOP mea-
surements in this study was approximately 10mmHg. There
are probably multiple sources for this high variability. First,
there is a natural time-course to the IOP response from
treatment with corticosteroids. Because the patients for this
study were generally identified after they had experienced
an IOP increase, it was not always possible to standardize
the time of AA administration relative to the initial IOP in-
crease. Furthermore, this variability could be exacerbated by
differences in the type, dose, route of administration, history
of vitrectomy, and bolus versus chronic exposure for the
corticosteroid treatment, although as noted in the results, the
majority of patients had been treated with triamcinolone
acetonide. Second, the successful administration of an AJD is
dependent on the skill and experience of the investigator.
This is a difficult variable to quantify a priori, however, all
injections for this study were video recorded and reviewed
by the sponsor. Feedback was given to the investigators for
each injection. It was found to be generally true that the more
experience (greater number of injections) an investigator had
with the technique, the better the quality of the injection. This
qualitative view is supported by the data shown in Fig. 3.
There were more treatment successes at mid- and high-
enrolling sites, than for low-enrolling sites. Third, individual
differences in steroid responsiveness are well known and
thought to have a genetic component.23–25 It is likely that
response to AA is also dependent on an individual’s geno-
type. We believe further study is warranted to explore this
possibility.
It is interesting that the 15mg AA middle dose pro-
vided better IOP-lowering efficacy, and more sustained IOP-
control than the 30mg AA high dose. One explanation could
be that the 15mg dose is pharmacologically optimal with
diminished efficacy at higher doses. We do not believe this is
likely. Robin et al. used a dose of 24mg administered pre-
cisely as described here and found it to provide a mean IOP
reduction of 14mmHg at 1 month for steroid-induced ocular
hypertension patients, and between 8 and 9mmHg for up to
6 months in patients with open-angle glaucoma.14,16 Ad-
ditionally, Candia et al. successfully prevented prednisolone-
induced IOP elevation in steroid-responsive ovine eyes using
a dose of 75mg AA.15 Our feeling is that the low perfor-
mance of the 30mg AA group relative to the 15mg AA
group is a random outcome likely due to the high variability
observed in the data, and the relatively small sample size
employed in this study. The 3mg treatment group is statis-
tically and numerically indistinguishable from vehicle in
IOP-lowering efficacy at all time points (Table 2). If the 3mg
AA treatment could thus be considered a subclinical dose,
and the 15 and 30mg groups considered active, pooling of
the data for the vehicle and 3mg groups and for the 15
and 30mg groups demonstrates a mean IOP reduction
of 3.2mmHg (vehicle + 3mg, N = 35) versus 8.4mmHg
(15 + 30mg, N = 35; P = 0.027, 1-tailed t-test). Although this is
a post hoc analysis, the approximate 5mmHg reduction
relative to vehicle may be a more accurate estimate of the
IOP-lowering benefit that could be expected in patients with
steroid-induced IOP elevation.
We here provide data from a randomized controlled study
demonstrating that AA can be of benefit to some patients
requiring treatment with corticosteroids, but suffering from
the common side effect of elevated IOP. Treatment with AA
may provide long-lasting IOP-control for such patients from
a single administration. Adverse events were found to be
nonserious and easily tolerated. Development of long-acting
IOP-lowering therapies like AA is clearly needed.
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